Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: The blocking and bridging strategy

Thrombosis Research

Volumn 132, Issue 1, 2013, Pages

  Christ, Günter ^a   Hafner, Thomas ^a   Siller Matula, Jolanta M ^b   Francesconi, Marcel ^a   Grohs, Katharina ^a   Wilhelm, Eva ^a   Podczeck Schweighofer, Andrea ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Abciximab; Dual antiplatelet therapy; Platelet function; Primary percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ABCIXIMAB; ACS; ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ADP; DUAL ANTIPLATELET THERAPY; GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR; GPI; MEA; MULTIPLE ELECTRODE AGGREGOMETRY; NON-ST-ELEVATION MYOCARDIAL INFARCTION; NSTEMI; PCI; PERCUTANEOUS CORONARY INTERVENTION; PLATELET FUNCTION; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; ST-ELEVATION MYOCARDIAL INFARCTION; STEMI; THROMBIN RECEPTOR-ACTIVATING PEPTIDE; TRAP;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE;

EID: 84881314865     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.05.029     Document Type: Article

References (24)

1. P.G. Steg, S.K. James, D. Atar, L.P. Badano, C. Blömstrom-Lundqvist, and M.A. Borger ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 33 2012 2569 2619
2. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation N Engl J Med 330 1994 956 961
4. J.D. Marmur, C.A. Mitre, E. Barnathan, and E. Cavusoglu Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial Am Heart J 152 2006 876 881 (Pubitemid 44632954)
5. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
6. M. Valgimigli, G. Campo, M. Tebaldi, M. Monti, S. Gambetti, and A. Scalone Randomized, double-blind comparison of the effects of abciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting J Thromb Haemost 8 2010 1903 1911
7. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K.C. Theodoropoulos, and G. Makris Randomized assessment of Ticagrelor versus Prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
8. M. Valgimigli, M. Tebaldi, G. Campo, S. Gambetti, L. Bristot, and M. Monti Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial JACC Cardiovasc Interv 5 2012 268 277
9. R. Piccolo, Y.L. Gu, A.Z. Iversen, A. Dominguez-Rodriguez, B.J. de Smet, and K.D. Mahmoud Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient data pooled analysis of randomised studies Heart 2012 10.1136/heartjnl-2011- 301101 [Epub May 24]
10. H. Thiele, J. Wöhrle, R. Hambrecht, H. Rittger, R. Birkemeyer, and B. Lauer Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial Lancet 379 2012 923 931
11. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate J Am Coll Cardiol 56 2010 919 933
12. G. Parodi, R. Marcucci, R. Valenti, A.M. Gori, A. Migliorini, and B. Giusti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
13. M. Orban, R.A. Byrne, J. Hausleiter, K.L. Laugwitz, and D. Sibbing Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock Thromb Haemost 106 2011 555 558
14. O. Toth, A. Calatzis, S. Penz, H. Losonczy, and W. Siess Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood Thromb Haemost 96 2006 781 788 (Pubitemid 44883819)
15. D.E. Candia Mechanisms of platelet activation by thrombin: a short history Thromb Res 129 2012 250 256
16. J.H. Chesebro, G. Knatterud, R. Roberts, J. Borer, L.S. Cohen, and J. Dalen Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase Circulation 76 1987 142 154 (Pubitemid 17093202)
17. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J Am Coll Cardiol 52 2008 1557 1563
18. J.M. Siller-Matula, M. Francesconi, C. Dechant, B. Jilma, G. Maurer, and G. Delle-Karth Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study Int J Cardiol 2012 10.1016/j.ijcard.2012.05.040 [Epub May 30]
19. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, and D. Dudek Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230 (Pubitemid 351724451)
20. S.D. Wiviott, D. Trenk, A.L. Frelinger, M. O'Donoghue, F.J. Neumann, and A.D. Michelson Prasugrel compared with high loading- and maintenance- dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932 (Pubitemid 350291199)
21. P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, and C. Wei Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
22. I. Cornelissen, D. Palmer, T. David, L. Wilsbacher, C. Concengo, and P. Conley Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis Proc Natl Acad Sci U S A 107 2010 18605 18610
23. R.P. Kreutz, J.A. Breall, Y. Kreutz, J. Owens, D. Lu, and I. Bolad Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response Thromb Res 130 2012 198 202
24. H. Haberstock-Debic, P. Andre, S. Mills, D.R. Phillips, and P.B. Conley A Clopidogrel-Insensitive Inducible Pool of P2Y12 Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y12 Antagonist J Pharmacol Exp Ther 339 2011 54 61